These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 35105949)

  • 1. Evaluation of the dystrophin carboxy-terminal domain for micro-dystrophin gene therapy in cardiac and skeletal muscles in the DMD
    Bourdon A; François V; Zhang L; Lafoux A; Fraysse B; Toumaniantz G; Larcher T; Girard T; Ledevin M; Lebreton C; Hivonnait A; Creismeas A; Allais M; Marie B; Guguin J; Blouin V; Remy S; Anegon I; Huchet C; Malerba A; Kao B; Le Heron A; Moullier P; Dickson G; Popplewell L; Adjali O; Montanaro F; Le Guiner C
    Gene Ther; 2022 Sep; 29(9):520-535. PubMed ID: 35105949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of α1-syntrophin and α-dystrobrevin in skeletal muscles of mdx mice.
    Koo T; Malerba A; Athanasopoulos T; Trollet C; Boldrin L; Ferry A; Popplewell L; Foster H; Foster K; Dickson G
    Hum Gene Ther; 2011 Nov; 22(11):1379-88. PubMed ID: 21453126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
    Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
    Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy.
    Farrokhi V; Walsh J; Palandra J; Brodfuehrer J; Caiazzo T; Owens J; Binks M; Neelakantan S; Yong F; Dua P; Le Guiner C; Neubert H
    Gene Ther; 2022 Nov; 29(10-11):608-615. PubMed ID: 34737451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model.
    Rodino-Klapac LR; Janssen PM; Shontz KM; Canan B; Montgomery CL; Griffin D; Heller K; Schmelzer L; Handy C; Clark KR; Sahenk Z; Mendell JR; Kaspar BK
    Hum Mol Genet; 2013 Dec; 22(24):4929-37. PubMed ID: 23863459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice.
    Koo T; Popplewell L; Athanasopoulos T; Dickson G
    Hum Gene Ther; 2014 Feb; 25(2):98-108. PubMed ID: 24191945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human dystrophin expressing chimeric (DEC) cell therapy ameliorates cardiac, respiratory, and skeletal muscle's function in Duchenne muscular dystrophy.
    Siemionow M; Langa P; Harasymczuk M; Cwykiel J; Sielewicz M; Smieszek J; Heydemann A
    Stem Cells Transl Med; 2021 Oct; 10(10):1406-1418. PubMed ID: 34291884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined gene therapy via VEGF and mini-dystrophin synergistically improves pathologies in temporalis muscle of dystrophin/utrophin double knockout mice.
    Xin C; Chu X; Wei W; Kuang B; Wang Y; Tang Y; Chen J; You H; Li C; Wang B
    Hum Mol Genet; 2021 Jun; 30(14):1349-1359. PubMed ID: 33987645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRPC3, but not TRPC1, as a good therapeutic target for standalone or complementary treatment of DMD.
    Creisméas A; Gazaille C; Bourdon A; Lallemand MA; François V; Allais M; Ledevin M; Larcher T; Toumaniantz G; Lafoux A; Huchet C; Anegon I; Adjali O; Le Guiner C; Fraysse B
    J Transl Med; 2021 Dec; 19(1):519. PubMed ID: 34930315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effect of human mini-dystrophin in transgenic mdx mice improves muscle physiological function.
    Chu X; Li J; Qiao C; Wang J; Wang Y; Jiang XC; You H; Xiao X; Wang B
    FASEB J; 2021 Jun; 35(6):e21628. PubMed ID: 33982338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the
    Potter RA; Griffin DA; Heller KN; Peterson EL; Clark EK; Mendell JR; Rodino-Klapac LR
    Hum Gene Ther; 2021 Apr; 32(7-8):375-389. PubMed ID: 33397205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for duchenne muscular dystrophy.
    Ahmad A; Brinson M; Hodges BL; Chamberlain JS; Amalfitano A
    Hum Mol Genet; 2000 Oct; 9(17):2507-15. PubMed ID: 11030755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
    Maruyama R; Yokota T
    Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy.
    Zhang Y; Yue Y; Li L; Hakim CH; Zhang K; Thomas GD; Duan D
    Hum Mol Genet; 2013 Sep; 22(18):3720-9. PubMed ID: 23681067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of dystrophin and utrophin gene transfer in immunocompetent muscular dystrophy (mdx) mice.
    Ebihara S; Guibinga GH; Gilbert R; Nalbantoglu J; Massie B; Karpati G; Petrof BJ
    Physiol Genomics; 2000 Sep; 3(3):133-44. PubMed ID: 11015608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD).
    Athanasopoulos T; Graham IR; Foster H; Dickson G
    Gene Ther; 2004 Oct; 11 Suppl 1():S109-21. PubMed ID: 15454965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy.
    Li S; Kimura E; Ng R; Fall BM; Meuse L; Reyes M; Faulkner JA; Chamberlain JS
    Hum Mol Genet; 2006 May; 15(10):1610-22. PubMed ID: 16595609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice.
    Odom GL; Gregorevic P; Allen JM; Finn E; Chamberlain JS
    Mol Ther; 2008 Sep; 16(9):1539-45. PubMed ID: 18665159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy.
    Chesshyre M; Ridout D; Hashimoto Y; Ookubo Y; Torelli S; Maresh K; Ricotti V; Abbott L; Gupta VA; Main M; Ferrari G; Kowala A; Lin YY; Tedesco FS; Scoto M; Baranello G; Manzur A; Aoki Y; Muntoni F
    J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1360-1372. PubMed ID: 35083887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Gene therapy for muscular dystrophy].
    Takeda S
    No To Hattatsu; 2004 Mar; 36(2):117-23. PubMed ID: 15031985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.